| Filed On | Filing |
|---|---|
| 12 Nov 2026 |
8-K: Results of Operations and Financial Condition
CNTY-813, an iPSC-derived islet replacement therapy for T1D, presented new nonclinical data at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) and remains on track for IND submission in 4Q 2026; initi... |
| 12 Nov 2026 | 10-Q |
| 05 Nov 2026 |
Form 4: Carr Douglas, SVP Finance & Operations
Sold 266 shares ($404) |
| 03 Nov 2026 | 144 |
| 02 Oct 2026 |
8-K: Regulation FD Disclosure; Other Events
CNTY - 813: Scalable Production of Allo - Evasion TM 5.0 - Engineered iPSC Islets for Off - the - Shelf Cell Therapies G. Grant Welstead, PhD SVP, Head of Research |
| 15 Sep 2026 |
Form 4: Russotti Gregory, See Remarks
Sold 2,587 shares ($4.99K) |
| 15 Sep 2026 |
Form 4: Carr Douglas, SVP Finance & Operations
Sold 1,658 shares ($3.2K) |
| 15 Sep 2026 |
Form 4: Pfeiffenberger Brent, Director
Gave up 13,850 shares to cover exercise price or tax ($26.9K) |
| 14 Sep 2026 | 144 |
| 14 Sep 2026 | 144 |
| 10 Sep 2026 |
Form 4: Truitt Joseph, Director
Granted 148,000 Stock Option (right to buy) |
| 10 Sep 2026 |
Form 3: Truitt Joseph, Director
No securities owned |
| 09 Sep 2026 |
Form 4: Pfeiffenberger Brent, Director
Gave up 463 shares to cover exercise price or tax ($977) |
| 09 Sep 2026 |
Form 4: Russotti Gregory, See Remarks
Sold 534 shares ($1.09K) |
| 09 Sep 2026 |
Form 4: Carr Douglas, SVP Finance & Operations
Sold 254 shares ($521) |
| 09 Sep 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
PHILADELPHIA, September 9, 2026 - Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes (T1... |
| 08 Sep 2026 | 144 |
| 18 Aug 2026 |
Form 4: Pfeiffenberger Brent, Director
Gave up 31,172 shares to cover exercise price or tax ($59.9K) |
| 12 Aug 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Completed pre-IND meeting with the FDA for CNTY-813, an iPSC-derived islet replacement therapy with functional cure potential in type 1 diabetes (T1D); IND submission on track for 4Q 2026 |
| 12 Aug 2026 | 10-Q |
Loading...